Roche Could Lose $1 Billion on Revoked Avastin Breast Cancer Use (RHHBY)

by Benzinga Staff
July 21, 2010 9:05 AM | 1 min read |
Roche Holding AG’s RHHBY top selling cancer drug Avastin may lose $1 billion in annual revenue if U.S. regulators revoke approval of the drug for use in breast cancer after a panel voted 12-1 yesterday to rescind it in Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAGlobalPre-Market OutlookMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!